Table 2 Characteristics of endogenous invasive MRSA infections
Patient no. | Type of infection | Period | Date of infection | Delay between admission and infection (days) | Delay between positive MRSA screening and infection (days) | Antibiotic treatment (Y/N) | Death (Y/N) | Time between infection and death (days) |
|---|---|---|---|---|---|---|---|---|
1 | Pneumonia | P1 | 4 Sep 2000 | 26 | 7 | Y (vancomycin) | N | |
2 | Bacteraemia | P2 | 14 Aug 2001 | 8 | 7 | Y (vancomycin) | Y | 15 |
3 | Pneumonia | P2 | 29 Aug 2001 | 37 | 6 | Y (vancomycin) | N | |
4 | Pneumonia | P2 | 29 Aug 2001 | 13 | 2 | N | Y | 0 |
5 | Endocarditis | P2 | 10 Oct 2001 | 6 | 6 | Y (vancomycin) | N | |
6 | Bacteraemia | P2 | 24 Dec 2001 | 18 | 13 | Y (vancomycin) | N | |
7 | Bacteraemia | P2 | 16 Feb 2002 | 8 | 5 | Y (vancomycin) | N | |
8 | Pneumonia | P2 | 1 Apr 2002 | 3 | 2 | Y (vancomycin) | N | |
9 | Pneumonia | P2 | 6 Jun 2002 | 13 | 13 | Y (vancomycin) | N | |
10 | Bacteraemia | P2 | 22 Jun 2002 | 26 | 26 | Y (vancomycin) | N | |
11 | Pneumonia | P2 | 6 Feb 2003 | 13 | 3 | Y (linezolid) | Y | 7 |
12 | Pneumonia | P2 | 24 Mar 2003 | 7 | 5 | Y (vancomycin) | N |